Epix Pegs Vasovist Approval In Second Half 2007 Following Second “Approvable” Letter
FDA’s action letter for the vascular imaging agent requires an additional clinical trial and a re-read of images from previous trials.
FDA’s action letter for the vascular imaging agent requires an additional clinical trial and a re-read of images from previous trials.